SOURCE: Horizon Pharma plc

Horizon Pharma plc

Horizon Pharma plc

March 20, 2015 08:00 ET

Horizon Pharma and the Chicago Innovation Awards to Ring The Nasdaq Stock Market Closing Bell

Celebrating Innovation in the Chicago Region

DEERFIELD, IL--(Marketwired - Mar 20, 2015) -  Horizon Pharma (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, will join the Chicago Innovation Awards, the Chicago region's foremost annual celebration of innovation, in New York City on Monday, March 23rd to ring the Closing Bell at The Nasdaq Stock Market. The event, arranged by the Chicago Innovation Awards, will emphasize the surge of innovation that is occurring in the Chicago region, and shine a spotlight on the organizations that make up its vibrant economy.

"This annual event is an excellent example of how the Chicago Innovation Awards celebrates the spirit of innovation in organizations across all industries, sizes and sectors," said Tom Kuczmarski, co-founder of the Chicago Innovation Awards.

"We congratulate Horizon Pharma for winning a Chicago Innovation Award, and applaud their commitment to innovation," said Dan Miller, fellow co-founder.

Joining Horizon Pharma will be other winners of the 2014 Chicago Innovation Awards, including: 640 Labs, alligatortek, Auctions By Cellular, Beltone, Caremerge, dough, Keeper Security, KENTECH, LMK Technologies, LuminAID, Mattersight, Options Away, Packback, Pangea, Radio Flyer, Rippleshot, Rise Interactive, Shiftgig, Strata Decision Technology, Swingbyte and ThinkCERCA.

"We were honored to win a Chicago Innovation Award last year for our work with DUEXIS," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "We support the Chicago Innovation Awards as it continues to foster and celebrate innovation across all Chicago business sectors."

Horizon Pharma was awarded a Chicago Innovation Award in October 2014 for the development of DUEXIS, which was a first-of-its-kind pharmaceutical product that combined prescription-strength ibuprofen with high-dose famotidine. DUEXIS is designed to address pain and inflammation associated with osteoarthritis and rheumatoid arthritis and to reduce the development of GI ulcers due to the NSAID component ibuprofen.

To learn more about the Chicago Innovation Award winners, watch their video testimonials.

For more on the history and inspiration for the Chicago Innovation Awards, click here.

About DUEXIS
DUEXIS, a proprietary single-tablet combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months. For more information, please visit www.DUEXIS.com.

The following details are from the DUEXIS (ibuprofen and famotidine) Prescribing Information. For more information, please see the Medication Guide and the full Prescribing Information for DUEXIS available at www.DUEXIS.com. Always talk with your health care provider if you have questions.

Approved Uses for DUEXIS
DUEXIS, a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.

Important Safety Information

  • Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, a component of DUEXIS, may increase the chance of a heart attack or stroke, which can be fatal. This chance increases with longer use and in people who have heart disease or risk factors for heart disease
  • DUEXIS should not be used before or after a type of heart surgery called coronary artery bypass graft (CABG)
  • NSAID-containing medications like DUEXIS may increase the chance of stomach and intestinal problems, such as bleeding or an ulcer. These problems can happen without warning and can lead to death. Older patients may have a greater chance of developing these problems

DUEXIS is not right for everyone. People who have had asthma, hives or an allergic reaction to aspirin or other NSAIDs should not take DUEXIS. Women in the late stages of pregnancy should not take DUEXIS. People who have had allergic reactions to medications like famotidine (histamine H2-receptor antagonists) should not take DUEXIS.

Tell your health care provider right away if you have signs of active bleeding (persistent and unexplained) while you are taking DUEXIS.

NSAID-containing medications like DUEXIS can cause high blood pressure or make existing high blood pressure worse, either of which can increase the chance of a heart attack or stroke. Your health care provider should check your blood pressure while you are taking DUEXIS.

Before you start taking DUEXIS, tell your health care provider if you have heart problems, kidney problems or liver problems or if you are taking medications for high blood pressure. DUEXIS can increase the chance of potentially significant liver injury and/or kidney injury, which may be fatal. Stop taking DUEXIS immediately and contact your health care provider if you experience any signs and/or symptoms of liver or kidney injury.

Serious allergic reactions, including skin reactions, can happen without warning and can be life threatening. Stop taking DUEXIS and consult your doctor immediately if you get a skin rash or if you start to have problems breathing or swallowing, or if you develop swelling of your face or throat.

The most common side effects of DUEXIS include nausea, diarrhea, constipation, upper abdominal pain and headache.

About Horizon Pharma
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.

About The Chicago Innovation Awards
The Chicago Innovation Awards, established in 2002, have grown from a single awards ceremony to a year-long series of events and activities designed to celebrate innovation in the Chicago region, educate people and organizations about the principles of innovation, and connect the corners of the economy by building relationships that strengthen companies, grow the economy and create jobs. The organization's expansion has included formation of the Chicago Innovation Foundation, which promotes innovation education and provides scholarships to college students each year, as well as The Innovators Connection, which connects large companies with Chicago-based start-ups.

For more information, visit www.chicagoinnovationawards.com.

Contact Information